BMS’s Opdivo Misses Again In Glioblastoma Phase III Trial
A second failure for BMS’s Opdivo in brain cancer leaves it with just one final chance in newly diagnosed disease, where the bar is lower.
You may also be interested in...
It's bad news for Israel's VBL as the company's lead gene-based biologic has failed in a critical Phase III trial in brain cancer – the pressure is on now for success with this drug candidate in ovarian cancer.
With at least two potential candidates being touted as potential best-in-class by their sponsors, the oral SERD market is shaping up to be highly competitive. Sanofi has taken an early lead in expanding the scope of its Phase III breast cancer program.
A decent 42% reduction in the risk of recurrence in high-risk early-stage BRCA mutated disease should open another new market for the leading PARP inhibitor. Data also hint at a survival benefit to come.